Scholar Rock
SRRK · Nasdaq · United States
Share price · SRRK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SRRK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+6.5%
- 10 Nov 2026-6.9%
- 9 Nov 2026+9.8%
Nothing announced by SRRK that day or the session before.
- 5 Oct 2026-7.3%
Nothing announced by SRRK that day or the session before.
- 14 Sep 2026-6.4%
- 8 Sep 2026+3.8%
Nothing announced by SRRK that day or the session before.
- 18 Aug 2026+5.1%
Nothing announced by SRRK that day or the session before.
- 6 Aug 2026+10.0%
- 31 Mar 2026+14.1%
- 19 Mar 2026+14.4%
Nothing announced by SRRK that day or the session before.
Share of unusual movement by asset
For each asset, the share of SRRK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
apitegromab(Isembyld) | Approved | Myostatin (pro/latent form)Monoclonal antibody | ObesitySpinal Muscular Atrophy |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
June 2028 (1)
What to watch
November 2028 (1)
What to watch
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $54M | $370M+ $47M short-term inv. | $107M-$82M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $58M | $441M+ $55M short-term inv. | $110M-$70M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $52M | $434M+ $49M short-term inv. | $106M-$82M operating cash flow | report ↗ |
| 2025-Q3 | — | $50M | $291M+ $83M short-term inv. | $102M-$69M operating cash flow | report ↗ |
| 2025-Q2 | — | $62M | $155M+ $142M short-term inv. | $110M-$77M operating cash flow | report ↗ |
| 2025-Q1 | — | $49M | $140M+ $226M short-term inv. | $75M-$79M operating cash flow | report ↗ |
| 2024-Q3 | — | $49M | $79M+ $63M short-term inv. | $64M-$52M operating cash flow | report ↗ |
| 2024-Q2 | — | $42M | $96M+ $97M short-term inv. | $59M-$49M operating cash flow | report ↗ |
| 2024-Q1 | — | $43M | $94M+ $146M short-term inv. | $57M-$50M operating cash flow | report ↗ |
| 2023-Q3 | — | $30M | $70M+ $151M short-term inv. | $42M-$32M operating cash flow | report ↗ |
| 2023-Q2 | — | $27M | $111M+ $141M short-term inv. | $38M-$33M operating cash flow | report ↗ |
| 2023-Q1 | — | $30M | $154M+ $124M short-term inv. | $39M-$43M operating cash flow | report ↗ |
| 2022-Q3 | — | $33M | $136M+ $211M short-term inv. | $43M-$26M operating cash flow | report ↗ |
| 2022-Q2 | — | $32M | $308M+ $65M short-term inv. | $44M-$35M operating cash flow | report ↗ |
| 2022-Q1 | $33M | $29M | $103M+ $110M short-term inv. | $8.0M-$43M operating cash flow | report ↗ |
| 2021-Q3 | $5.5M | $31M | $179M+ $70M short-term inv. | $38M-$36M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $208M | $327M+ $44M short-term inv. | $94M-$300M operating cash flow | report ↗ |
Scholar Rock recorded no revenue in 2025 or 2024, with R&D expense of $208.44M, up 12.9% YoY. Cash and equivalents were $327.33M, while cash, cash equivalents, and marketable securities were $367.6M at year-end. The full-year net loss was $377.94M, including a Q4 net loss of $91.0M.
The company expects to resubmit the apitegromab BLA and launch in the U.S. in 2026 following a successful FDA reinspection of Catalent Indiana; the recent FDA meeting was constructive, with no additional corrective actions requested. The EMA decision on the apitegromab MAA is expected in mid-2026, with European launch planned for H2 2026 beginning in Germany. A new debt facility provides up to $550M in non-dilutive capital. Other milestones include Phase 2 FORGE initiation in FSHD in mid-2026, ongoing Phase 2 OPAL enrollment, SRK-439 Phase 1 topline data in H2 2026, and a supplemental BLA for a second fill-finish facility later in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $185M | $180M+ $259M short-term inv. | $62M-$201M operating cash flow | report ↗ |
| 2023-FY | — | $122M | $104M+ $178M short-term inv. | $41M-$145M operating cash flow | report ↗ |
| 2022-FY | $33M | $124M | $106M+ $212M short-term inv. | $34M-$133M operating cash flow | report ↗ |
| 2021-FY | $19M | $108M | $215M+ $40M short-term inv. | $33M-$127M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($12.0M), 38 sales ($19.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-26 | AKKARAJU SRINIVAS · director | Open-market purchase | 48,988 | $41.59 | $2.0M | Form 4 |
| 2026-10-26 | AKKARAJU SRINIVAS · director | Open-market purchase | 97,982 | $41.59 | $4.1M | Form 4 |
| 2026-10-23 | AKKARAJU SRINIVAS · director | Open-market purchase | 47,000 | $41.31 | $1.9M | Form 4 |
| 2026-10-23 | AKKARAJU SRINIVAS · director | Open-market purchase | 94,000 | $41.31 | $3.9M | Form 4 |
| 2026-10-23 | AKKARAJU SRINIVAS · director | Open-market purchase | 500 | $41.82 | $21K | Form 4 |
| 2026-10-23 | AKKARAJU SRINIVAS · director | Open-market purchase | 1,000 | $41.82 | $42K | Form 4 |
| 2026-09-24 | Woods Keith · Chief Operating Officer | Gift | 48,034 | — | — | Form 4 |
| 2026-09-21 | Hallal David · director, Chief Executive Officer | Gift | 36,652 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 272 reporting institutions held 133.8M shares ($6.3B, 109.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 17,243,152 | $847.7M |
| 2 | Siren, L.L.C. | 10,825,013 | $532.2M |
| 3 | Redmile Group, LLC | 9,066,621 | $445.7M |
| 4 | BlackRock, Inc. | 7,469,293 | $367.2M |
| 5 | SAMSARA BIOCAPITAL, LLC | 6,897,652 | $339.1M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 6,717,655 | $330.2M |
| 7 | Orbis Allan Gray Ltd | 4,179,983 | $205.5M |
| 8 | STATE STREET CORP | 4,031,317 | $198.2M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3,891,347 | $191.3M |
| 10 | Bellevue Group AG | 3,584,573 | $176.2M |
| 11 | JENNISON ASSOCIATES LLC | 3,340,492 | $164.2M |
| 12 | JANUS HENDERSON GROUP PLC | 2,236,837 | $109.9M |
| 13 | EVENTIDE ASSET MANAGEMENT, LLC | 2,197,385 | $107.9M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2,149,036 | $105.7M |
| 15 | STEMPOINT CAPITAL LP | 2,070,992 | $101.8M |